Dr. Antoni Ribas develops groundbreaking immunotherapies, interventions that mobilize the immune system to fight cancer. By studying the cellular mechanisms driving—or inhibiting—an immune response to cancer, Dr. Ribas uncovers techniques to activate our natural defenses.
Dr. Ribas’s discoveries have helped many patients fight cancer when nothing else worked.
To allow T cells to fight cancer, Dr. Ribas tried blocking the programmed death-1 (PD-1) protein, a receptor cancer manipulates to evade immune response.
He found that pembrolizimab—a drug developed by Merck to block PD-1—helped many patients fight their cancer. Read more in PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance, published in Nature.
However, PD-1 blockade did not help all patients, and Dr. Ribas wanted to know why.
Dr. Ribas combined pembrolizimab with an oncolytic virus, injected at the tumor site. He believed the virus—a foreign invader—would lure T cells toward cancer tumors and boost the efficacy of PD-1 blockade.
The combined therapy increased T cells at tumor sites and stimulated a complete response in 33% of patients. Read more in Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, the first phase 1 clinical trial report ever published in Cell.
With his sights set on optimizing cancer immunotherapy, Dr. Ribas plans to learn as much as he can by testing new treatments, including adoptive cell transfer therapy, and investigating the underlying immune system mechanisms that render treatments effective or ineffective.
Dr. Ribas wants to uncover the limits and potentials of the human immune system in the fight against cancer, a pursuit rooted in scientific understanding. When it comes to cancer, Dr. Ribas believes we can always know more about getting the immune system to fight back.
"Our progress did not happen by chance; it happened by understanding science, understanding the immune system, and turning that understanding into treatments."
- Dr. Antoni Ribas